pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,540 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1876Endpoints1458Fierce Biotech771BioSpace762BioPharma Dive551raps249onclive165fda recalls122
therapy area
allOncology12974Rare Disease3368Immunology3056Cardiology2860Hematology2314Pulmonology2256Vaccines
  • Democrats’ midterm sweep positions Bernie Sanders to steer Senate health committee, raising hopes for major FDA reforms
    The recent midterm elections delivered a decisive victory for Democrats, giving the party control of Congress and setting the stage for sweeping health‑care changes. Among the anticipated shifts,…
    STAT · 14d agoRegulatoryNeutral↗ source
  • T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugs
    T-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing. The capital will be used to generate proof-of-concept data for its lead bispec…
    BioPharma Dive · 14d agoDealPositive↗ source
← prev
page 22 of 222
next →
fda medwatch116
globenewswire health73
fda press62
1861
Psychiatry & CNS1235
Ophthalmology1140
Endocrinology & Metabolism809
Pain793
Nephrology788
  • China clamps down on investigator-initiated biotech trials after patient deaths, halting rare-disease studies
    Chinese regulators have introduced new rules that sharply limit investigator‑initiated biotech trials after a series of patient deaths were reported this summer. The policy shift is intended to tig…
    STAT · 14d agoRegulatoryNegative↗ source
  • Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemia
    Alethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round. The capital will fund the company’s lead program, an antibody designed to treat ess…
    Endpoints · 14d agoDealPositive↗ source
  • Alethio Therapeutics secures $90 million to develop treatments for rare blood cancers
    Alethio Therapeutics, a UK based biotechnology startup, announced it has raised $90 million in new financing. The capital will be used to advance its pipeline targeting myeloproliferative neoplasm…
    BioPharma Dive · 14d agoDealPositive↗ source
  • T-Therapeutics raises $133 million from Sanofi, J&J, Merck KGaA and Eli Lilly for TCR cancer and autoimmune programs
    T-Therapeutics, a UK biotech focused on T-cell receptor therapies for cancer and autoimmune diseases, announced it has raised $133 million in financing. The round is led by Sanofi with participati…
    Endpoints · 14d agoDealPositive↗ source
  • One in Five Biopharma Workers Have Been Laid Off Multiple Times, Survey Shows
    A recent BioSpace LinkedIn poll found that 64% of biotech and pharma professionals have been laid off in the past five years, and 22% have experienced job loss at least twice. Those who have faced…
    BioSpace · 14d agoLayoffsNegative↗ source
  • PhRMA spent roughly $59 million on search ads to shape public views on drug pricing
    PhRMA, the trade group for U.S. drug makers, spent about $59 million on search advertising over a recent seven‑year period to influence how Americans perceive prescription‑drug costs. Roughly $32…
    STAT · 14d agoNeutral↗ source
  • New treatments for preeclampsia move closer to patients
    Emily Chaddock’s experience highlights the danger of severe preeclampsia, a pregnancy complication that can threaten both mother and baby. At 27 weeks she developed the condition, leading to a rapi…
    Endpoints · 14d agoPositive↗ source
  • Democratic doctors celebrate gains as MAHA’s future remains uncertain after election
    The STAT+ D.C. Diagnosis newsletter reports that doctors aligned with the Democratic Party secured notable wins in recent political battles. At the same time, the Medicare for All (MAHA) initiativ…
    STAT · 14d agoNeutral↗ source
  • ProMis shares tumble after competitor's Alzheimer trial failure, CEO calls reaction overblown
    ProMis Neurosciences, developer of an amyloid‑targeting Alzheimer’s therapy, saw its stock plunge sharply last week. The decline came after Acumen Pharmaceuticals announced that its own amyloid‑ta…
    STAT · 14d agoNegative↗ source
  • Generate Biomedicines CEO touts AI-driven shrinkage of CAR-T cell engines as huge opportunity
    Generate Biomedicines' chief executive highlighted a "huge opportunity" after the company applied Anthropic's Claude AI platform to make its CAR‑T cell engines smaller. The Flagship‑founded biotec…
    Fierce Biotech · 14d agoPositive↗ source
  • Health systems grapple with AI chatbot use, some block tools while others consider in-house solutions
    Free AI chatbots designed for clinicians, such as OpenEvidence, Doximity Ask and ChatGPT for Clinicians, have become popular, with hundreds of thousands of doctors turning to them for clinical guid…
    STAT · 14d agoRegulatoryNeutral↗ source
  • Agios to cut over 202 R&D positions as it awaits FDA decision on sickle cell drug
    Agios Pharmaceuticals said it will eliminate more than 100 research and development positions by the end of 2026, cutting its R&D workforce by roughly 35% from 2025 levels. The company entered the…
    Fierce Biotech · 14d agoLayoffsNegative↗ source
  • Cloudbreak Pharma’s Phase 3 Eye Drop Shows Significant Benefit in Pterygium Trial
    Cloudbreak Pharma reported that its phase 3 trial of CBT-001, a multi‑kinase inhibitor eye drop for pterygium, met both co‑primary endpoints. The study compared two doses of CBT-001 given twice da…
    Fierce Biotech · 14d agoPositive readoutPositive↗ source
  • AAFP chief urges Congress to add oversight to CDC vaccine advisory panel
    Shawn Martin, CEO of the American Academy of Family Physicians, said the CDC’s Advisory Committee on Immunization Practices (ACIP) has faced more than a year of turmoil. He is urging Congress to e…
    Endpoints · 14d agoRegulatoryNeutral↗ source
  • STAT+: Beyond statins, one drug lowered heart attack risk by 20%
    A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."
    STAT · 14d agoRegulatoryNeutral↗ source
  • Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunch
    Vivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…
    Fierce Biotech · 14d agoDealNeutral↗ source
  • Trump administration ends contracts with two No Surprises Act arbitrators over performance failures
    The federal government announced that two organizations that handle disputes under the No Surprises Act will no longer be allowed to accept new cases, saying they failed to meet required performanc…
    STAT · 14d agoRegulatoryNegative↗ source
  • Ellipsis Health acquires Kouper Health to expand AI voice call capabilities
    Ellipsis Health, a startup that builds voice-based artificial intelligence tools for healthcare, announced it has purchased Kouper Health. The deal reflects growing interest in AI systems that can…
    Endpoints · 14d agoDealNeutral↗ source
  • Medicare postpones controversial rule that bars hospitals from using third-party remote patient monitoring services
    Medicare announced it will finalize a proposal that delays an update to its remote patient monitoring (RPM) rule, despite strong opposition. The rule would prohibit hospitals and other providers f…
    STAT · 14d agoRegulatoryNegative↗ source
  • Podcast explores how intratumoral injections may spark systemic cancer immunity
    In a recent episode of BioSpace's Denatured podcast, host Jennifer C. Smith-Parker spoke with Lewis Bender, CEO of Intensity Therapeutics, and Paul-Peter Tak, president and CEO of Candel Therapeuti…
    BioSpace · 14d agoNeutral↗ source
  • BioSpace lists top 12 biopharma employers hiring in July 2026
    BioSpace released a list of the twelve biopharma firms with the most job postings in July 2026. The list includes AbbVie, Regeneron, Amgen, Eli Lilly, Sanofi, Novo Nordisk, Moderna, Insmed, Freder…
    BioSpace · 14d agoNeutral↗ source
  • Ballot measures on abortion, marijuana and transgender youth care highlight political divides in 2026 midterms
    Voters in the 2026 midterm elections faced a slate of state health policy ballot measures that addressed abortion rights, marijuana legalization, science funding bonds and care for transgender yout…
    STAT · 14d agoNeutral↗ source
  • MAHA movement faces electoral defeat as its political influence wanes
    The opinion piece declares that the original MAHA initiative, dubbed MAHA 1.0, has effectively ended after recent midterm elections, and suggests a new phase, MAHA 2.0, may emerge. At least eleven…
    STAT · 14d agoNegative↗ source